A5011234127- Cervical Cancer and HPV Research
- Chronic Myeloid Leukemia Treatments
- Immunotherapy and Immune Responses
- Virus-based gene therapy research
- Chronic Lymphocytic Leukemia Research
- Hepatitis B Virus Studies
- Acute Lymphoblastic Leukemia research
- Herpesvirus Infections and Treatments
- Eosinophilic Disorders and Syndromes
- Animal Virus Infections Studies
- vaccines and immunoinformatics approaches
- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Transgenic Plants and Applications
- Poxvirus research and outbreaks
- T-cell and Retrovirus Studies
- Monoclonal and Polyclonal Antibodies Research
- interferon and immune responses
- Genital Health and Disease
- Synthesis of β-Lactam Compounds
- Microbial infections and disease research
- Animal Disease Management and Epidemiology
- Molecular Biology Techniques and Applications
- Mast cells and histamine
- Viral Infectious Diseases and Gene Expression in Insects
Heidelberg University
2015-2024
German Cancer Research Center
2015-2024
DKFZ-ZMBH Alliance
2010-2024
Institute of Medical Microbiology and Hygiene
2023
Johannes Gutenberg University Mainz
1995-2021
University Hospital Ulm
2020
Leibniz Institute of Virology (LIV)
2020
University Hospital Heidelberg
2006-2019
Medizinische Fakultät Mannheim
2008-2017
University Medical Centre Mannheim
2008-2015
Certain sexually transmitted human papillomavirus (HPV) types are causally associated with the development of cervical cancer. Our recent high-titer HPV pseudoviruses has made it possible to perform high-throughput in vitro screens identify infection inhibitors. Comparison a variety compounds revealed that carrageenan, type sulfated polysaccharide extracted from red algae, is an extremely potent inhibitor for broad range HPVs. Although carrageenan can inhibit herpes simplex viruses and some...
An increase in worldwide HPV vaccination could be facilitated if fewer than three doses of vaccine are as effective doses. We originally aimed to compare the immunogenicity and frequency persistent infection cervical precancerous lesions caused by vaccine-targeted after with two quadrivalent on days 1 180 or later, 1, 60, a cluster-randomised trial. Suspension recruitment due events unrelated our study meant that some enrolled girls not vaccinated received planned number vaccinations...
Background Dasatinib 100 mg once daily achieves intermittent BCR-ABL kinase inhibition and is approved for chronic-phase chronic myeloid leukemia patients resistant or intolerant to imatinib. To better assess durability of response tolerability dasatinib, data from a 2-year minimum follow-up dose-optimization study in are reported here.Design Methods In phase 3 study, 670 with resistance, intolerance, suboptimal imatinib were randomized dasatinib once-daily, 50 twice-daily, 140 70...
Toll-like receptor (TLR) ligands are being considered as adjuvants for the induction of antigen-specific immune responses, in design vaccines. Polyriboinosinic-polyribocytoidylic acid (poly I:C), a synthetic double-stranded RNA (dsRNA), is recognized by TLR3 and other intracellular receptors. Poly ICLC poly I:C analogue, which has been stabilized against serum nucleases that present plasma primates. I:C12U, another less toxic but also stable vivo than I:C, essential its recognition. To study...
The vast majority of chronic myeloid leukemia patients express a BCR-ABL1 fusion gene mRNA encoding 210 kDa tyrosine kinase which promotes leukemic transformation. A possible differential impact the corresponding transcript variants e13a2 (“b2a2”) and e14a2 (“b3a2”) on disease phenotype outcome is still subject debate. total 1105 newly diagnosed imatinib-treated were analyzed according to type at diagnosis (e13a2, n=451; e14a2, n=496; e13a2+e14a2, n=158). No differences regarding age, sex,...
The recent World Health Organization recommendation supporting single-dose of HPV vaccine will significantly reduce programmatic cost, mitigate the supply shortage, and simplify logistics, thus allowing more low- middle-income countries to introduce vaccine. From a perspective durability protection offered by be key consideration. primary objectives present study were determine whether recipients quadrivalent had sustained immune response against targeted types (HPV 6,11,16,18) at 10 years...
ABSTRACT Expression of the structural proteins L1 and L2 human papillomaviruses (HPV) is tightly regulated. As a consequence, attempts to express these prime-candidate genes for prophylactic vaccination against papillomavirus-associated diseases in mammalian cells by means simple DNA transfections result insufficient production viral antigens. Similarly, vivo using HPV or expression constructs produces only weak immune responses. In this study we demonstrate that transient type 16 can be...
The inability of papillomaviruses (PV) to replicate in tissue culture cells has hampered the study PV life cycle. We investigated virus-cell interactions by following two methods: (i) using purified bovine virions or human type 11 (HPV 11) virus-like particles (VLP) test binding eukaryotic and (ii) different VLP-reporter plasmid complexes HPV6b, HPV11 L1 L1/L2, HPV16 L1/L2 uptake into cell lines. Our studies showed that capsids bind a broad range dose-dependent manner. Binding can be blocked...
background: Mutations of the BCR-ABL tyrosine kinase domain constitute a major cause resistance to inhibitors in patients with chronic myeloid leukemia. We sought improve diagnostic armamentarium by screening and analyze dynamics mutated clones leukemia who experienced hematologic or cytogenetic relapse.Ninety-five relapsed during imatinib therapy were screened for mutations using sensitive denaturing high-performance liquid chromatography (D-HPLC) direct sequencing. To investigate D-HPLC...
The human papillomavirus (HPV) minor capsid protein L2 is a promising candidate for broadly protective HPV vaccine yet the titers obtained in most experimental systems are rather low. Here we examine potential of empty AAV2 particles (AAVLPs), assembled from VP3 alone, display epitopes to enhance their immunogenicity. Insertion neutralizing epitope (amino acids 17–36) HPV16 and HPV31 into at positions 587 453, respectively, permitted assembly AAV (AAVLP(HPV16/31L2)). Intramuscularly...
Serial quantification of BCR–ABL1 mRNA is an important therapeutic indicator in chronic myeloid leukaemia, but there a substantial variation results reported by different laboratories. To improve comparability, internationally accepted plasmid certified reference material (CRM) was developed according to ISO Guide 34:2009. Fragments (e14a2 fusion), BCR and GUSB transcripts were amplified cloned into pUC18 yield pIRMM0099. Six linearised solutions produced with the following copy number...
Background. We compared the immunogenicity and reactogenicity of Cervarix or Gardasil human papillomavirus (HPV) vaccines in adults infected with immunodeficiency virus (HIV). Methods. This was a double-blind, controlled trial randomizing HIV-positive to receive 3 doses at 0, 1.5, 6 months. Immunogenicity evaluated for up 12 Neutralizing anti–HPV-16/18 antibodies were measured by pseudovirion-based neutralization assay. Laboratory tests diary cards used safety assessment. The HPV-DNA status...
The human papillomavirus (HPV) capsid is composed of the major protein L1 and minor L2. During entry, HPV undergoes numerous conformational changes that result in endosomal uptake subsequent trafficking L2 complex with viral DNA to trans-Golgi network. To facilitate this transport, harbors a number putative motifs that, if capable direct interaction, would interact cytosolic host cell factors. These data imply portion becomes during infection. Using low concentration digitonin selectively...